Specialist Accreditation in Neurology, Ministry of Health, Singapore, 2000

Member of Royal College of Physicians (MRCP, United Kingdom), 1995

​MBBS National University of Singapore, 1990

• ​Senior Consultant, Department of Neurology, National Neuroscience Institute
• Director, Research, National Neuroscience Institute
• Programme Director, NNI Parkinson and Movement Disorders Clinical Programme
• Treasurer-elect, International Parkinson and Movement Disorder Society
• Co-Director, Parkinson’s Disease and Movement Disorders Centre, USA National Parkinson Foundation, International Centre of Excellence
• Adjunct Associate Professor, Duke-NUS Graduate Medical School, Singapore

• Dean’s Award for teaching excellence AY 2013/14, Yong Loo Lin School of Medicine, National University of Singapore
• Distinguished Team Award (team lead), Singhealth Excellence Award 2015
• President’s Distinguished Service Award 2015.  International Parkinson and Movement Disorders Society
• Singapore Health Quality Service Award 2016, Silver
• Distinguished Member Award.  The Japanese Society of Neurology. 57th Annual Meeting, 2016

• ​Epidemiology, clinical studies and clinical trials in Parkinson's disease and other movement disorders

Selected publications from more than 100 publications:

• Wen MC, Ng SY, Heng HS, Chao YX, Chan LL, Tan EK, Tan LC.  Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study.  Parkinsonism Relat Disord. 2016 Mar;24:63-8.
• Tan LC, Methawasin K, Tan EK, Tan JH, Au WL, Yuan JM, Koh WP.  Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study.  J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):86-92.
• Linda P. Oosterveld, John C. Allen Jr, Ebonne Y.L. Ng, Soo-Hoon Seah , Kay-Yaw Tay, Wing-Lok Au, Eng-King Tan,  Louis C.S. Tan.  Greater motor progression in Parkinson’s disease patients with LRRK2 risk variants.  Neurology. 2015 Sep 22;85(12):1039-42. 
• YJ Zhao, HL Wee, YH Chan, SH Seah, WL Au, PN Lau, EC Pica, SC Li, N Luo and LCS Tan.  Progression of Parkinson’s Disease as Evaluated by Hoehn and Yahr Stage Transition Times.  Mov Disord 2010; 25(6):710-716.
• LCS Tan, N Venketasubramanian, CY Hong, S Sahadevan, JJ Chin, ES Krishnamoorthy, AKY Tan, SM Saw.  Prevalence of Parkinson’s disease in Singapore: Chinese vs Malays vs Indians.  Neurology 2004; 62:1999-2004.

• A multicenter, double blind, randomised, placebo-controlled, single treatment cycle, parallel evaluation of the safety, efficacy and immunogenicity of two formulations of BOTOX purified neurotoxin complex, followed by a blinded active treatment extension up to two additional treatment cycles in patients with cervical dystonia. (Co-I; sponsor: Allergan. 2008-9).
• Singapore Millenium Foundation Translational Research Grant awarded to NNI ending 2013.  Co-PI for PD epidemiological and clinical research. 
• An Open-label, Multicentre, Multinational Study To Assess The Feasibility Of Switching Therapy From Pramipexole Or Ropinirole To The Rotigotine Transdermal System and Its Effect On Motor And Non-motor Symptoms In Subjects with Advanced Idiopathic Parkinson's Disease.  PI; Sponsor: UCB Biosciences GmbH, 2013.
• An Open-Label Study to Investigate the Safety and the Efficacy of Rotigotine Add-On Therapy with Low Doses of Pramipexole or Ropinirole in Patients with Advanced Parkinson's Disease.  PI; Sponsor: UCB Biosciences GmbH, 2013. 
• Co-PI in National Medical Research Council – Translational clinical research grant for Parkinson’s disease (2014-2019 – $25 Million).